Company Insights

ATR customer relationships

Explore interactive graphBrowse insights index

ATR customers relationship map

AptarGroup (ATR): Customer Relationships That Drive Durable Drug‑Delivery and Consumer Packaging Revenue

AptarGroup manufactures and sells dispensing, dosing and protection technologies across pharma, beauty and consumer segments and monetizes through product sales, long‑term supply agreements and service contracts that support development and regulatory pathways for drug delivery. Revenue derives from high‑volume closure and pump sales to consumer brands, recurring device royalties and development/service fees from pharmaceutical partners—a mix that delivers margin resilience and exposure to both stable consumer demand and faster‑growing drug‑delivery programs. For more relationship intelligence, see https://nullexposure.com/.

How Aptar's customer map defines the business model

Aptar operates as a manufacturer‑seller with embedded service capabilities for drug development; the company both supplies components at scale and offers engineering, regulatory and digital‑health services that accelerate commercialization. Key operating characteristics are:

  • Contracting posture: Evidence of efforts to secure longer‑term contracts and royalty streams supports predictable revenue and reduces tooling‑related volatility.
  • Geographic diversification: Sales are materially concentrated in Europe and North America, with meaningful Asia and Latin America exposure—supporting both scale and distribution risk mitigation.
  • Role breadth: Aptar functions as a manufacturer, seller and service provider to pharma clients, indicating both product margins and higher‑value services.
  • Customer concentration: Aptar reports ~5,000 customers with no single customer above 4% of 2025 net sales, implying breadth rather than single‑client dependency.

These signals combine into a hybrid model: large, recurring consumer component volumes underpin cash flow while pharma relationships provide higher‑margin product and service revenue when programs progress.

The customer roster — what investors should know

Below is a concise, relationship‑by‑relationship inventory drawn from Aptar’s public statements and news coverage. Each entry is a plain‑English summary with source context.

  • CastleVax — Aptar’s LuerVax and Spray Divider platforms are being used in CastleVax’s Phase II intranasal COVID‑19 vaccine trial to evaluate mucosal immunity in ~200 adults, indicating Aptar’s role as a supplier of nasal delivery technologies for clinical programs (Aptar Q4 2025 earnings call and subsequent transcript, Mar 2026).

  • Bausch + Lomb (Bausch and Lomb / BLCO / BHC) — Aptar signed an exclusive agreement for its “Beat the Blink” eye‑care delivery system for ophthalmology, positioning Aptar as the exclusive device partner with anticipated commercial availability following industrialization (Aptar Q4 2025 earnings call; Aptar product news, FY2026).

  • ENA Respiratory (Ena Respiratory / ENA Respiratory) — Aptar’s Unidose Powder Nasal Spray System is being deployed in ENA Respiratory’s Phase II antiviral program, demonstrating Aptar’s growing footprint in intranasal respiratory therapeutics (news coverage, March–May 2026).

  • Nasus Pharma / NSRX — Nasus expanded strategic collaboration with Aptar for its NS002 program, securing Unit Dose System technology and manufacturing capacity that support clinical development and planned commercialization (Nasus/GNW announcement and PR Newswire releases, FY2025–2026).

  • Coca‑Cola (KO) — Aptar supplies a spout closure with tamper‑evident technology used on Powerade, BonAqua and certain energy drinks in South Africa, reflecting consumer‑beverage closure supply at scale (Aptar Q4 2025 earnings call transcript, Mar 2026).

  • McCormick (MKC / MKC‑V) — McCormick launched Cholula Cremosa using Aptar’s flip‑top pour spout closure for North America, showing Aptar’s penetration in condiment closures and specification wins with major food brands (Aptar Q4 2025 earnings call coverage, Mar 2026).

  • Cipla — Cipla received U.S. FDA approval for an AB‑rated Ventolin generic that uses Aptar’s metered dose inhaler valve, highlighting Aptar’s role in enabling generic respiratory products through device supply (investing.com transcript coverage, FY2026).

  • Clorox (CLX) — Clorox adopted a custom actuator from Aptar on a daily airspray product in North America, illustrating how early prototyping and application‑specific engineering translate into consumer product wins (investing.com coverage, FY2026).

  • LTR Pharma Limited (LTP) — Aptar’s proprietary nasal delivery system is in LTR Pharma’s Phase II SPONTAN® study for erectile dysfunction, underlining Aptar’s commercial‑scale nasal device adoption across therapeutic areas (Aptar press release, May 2026).

  • Enable Injections — Aptar Digital Health was named preferred partner to deliver companion digital solutions for Enable’s on‑body enFuse system, expanding Aptar’s digital‑health service footprint across wearable drug‑delivery lifecycles (investing.com article, Apr 2026).

  • Milestone Pharmaceuticals (MIST) — Aptar’s Bidose nasal system delivers CARDAMYST (etripamil), the first self‑administered FDA‑approved nasal spray for PSVT, signaling Aptar’s capacity to support breakthrough regulatory milestones and commercialization (Aptar Q4 2025 earnings call and markets/Finviz reporting, Dec 2025–Mar 2026).

  • Christian Dior — Aptar supplies a prestige fragrance pump featured on Dior Addict, illustrating wins in the high‑end beauty market where product design and finish command premium pricing (investing.com transcript, FY2026).

  • Clarins — Clarins launched Double Serum Foundation using Aptar’s patented dual‑dispensing technology with progressive dosage, demonstrating Aptar’s innovation in beauty dispensing solutions (investing.com FY2026 coverage).

  • Abbott (ABT) — Aptar is involved with Abbott’s Libre and Lingo products, indicating supply of components for medical device ecosystems and integration into diabetes care platforms (investing.com transcript, FY2026).

  • Guerlain — Aptar’s spray technology supported Guerlain’s European launch of an alcohol‑free hybrid product line, reinforcing Aptar’s role in formulation‑sensitive beauty launches (investing.com FY2026 reporting).

  • Newman’s Own — Aptar provided a dispensing closure used on Newman’s Own barbecue sauces, reflecting wins in the retail food channel for dispensing innovation (investing.com FY2026 coverage).

  • Chanel — Aptar developed a custom premium Airless beauty pump for Chanel’s HYDRA BEAUTY Micro Serum in Europe, showing ability to deliver bespoke solutions for luxury brands (Aptar Q4 2025 earnings call, Mar 2026).

  • Unilever (UL / UNLVF) — Unilever selected Aptar’s high‑dose all‑plastic pump for Nexxus shampoo and conditioner across North America, exemplifying large, multi‑SKU consumer rollouts that generate steady unit volumes (Aptar Q4 2025 earnings call and related coverage, FY2026).

(Second relationship intelligence resource: for a consolidated view of Aptar’s partner exposure and sourcing, visit https://nullexposure.com/.)

Investment implications: what this mix means for ATR investors

  • Durable core revenues from consumer closures and pumps: Large CPG wins (Unilever, Coca‑Cola, McCormick, Clorox) translate into predictable unit volumes and manufacturing leverage.
  • Higher‑margin optionality from pharma programs: Multiple Phase II/III engagements (Milestone, LTR, ENA, CastleVax, Nasus) and device exclusives (Bausch + Lomb) create upside through tooling, royalties and services if programs commercialize. Regulatory successes like Milestone’s CARDAMYST illustrate this pathway to higher returns.
  • Geographic diversification reduces single‑market risk: Europe is the largest region (~49% of sales) but North America and Asia contribute meaningfully—supporting resilience to localized demand shocks.
  • Contract mix and concentration: Evidence of longer‑term contracts and a broad customer base means revenue predictability, but commercialization risk for pharma customers remains a binary upside driver. Operational execution on industrialization for exclusive pharma partnerships is a key near‑term monitor.

Bottom line

Aptar’s customer relationships combine stable, high‑volume consumer supply with strategic pharma partnerships that can re‑rate the business on successful product approvals and launches. For investors, the critical signals are the depth of pharma engagements, the pace of commercialization for exclusive platforms, and the continuity of large consumer rollouts that underpin cash generation. For ongoing monitoring of client wins and contract signals, visit https://nullexposure.com/.

Join our Discord